Opicapone for the treatment of Parkinson’s disease

  title={Opicapone for the treatment of Parkinson’s disease},
  author={Filipe Brogueira Rodrigues and Joaquim J. Ferreira},
  journal={Expert Opinion on Pharmacotherapy},
  pages={445 - 453}
ABSTRACT Introduction: Parkinson’s disease (PD) is a progressive neurodegenerative disease. The currently available treatment options only have a symptomatic effect. With disease progression almost all antiparkinsonian pharmacological classes are tried, but the gold standard of pharmacological management is still L-dopa. Various strategies can be used to raise the dopaminergic tone. Catechol-O-methyltransferase (COMT) inhibitors attain this goal by decreasing L-dopa peripheral metabolism. Areas… 

Opicapone for the treatment of Parkinson’s disease: an update

This article summarizes knowledge about a new third-generation COMT inhibitor, namely opicapone (OPC) (Search period: 2016–2019), and details the pharmacological profile of OPC and the results of completed clinical trials.


Despite availability of numerous effective drugs which provide short term relief; still research is going on to develop promising drugs and newer strategies to provide long term benefit by modifying the disease process.

Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease

Existing and emerging pharmacotherapies for motor symptoms in PD are outlined and newer medications and modes of delivery continue to be researched and added to the therapeutic armamentarium.

Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease

This study provides Class III evidence that for patients with Parkinson disease and end-of-dose motor fluctuations, long-term use of opicapone is well tolerated and reduces “off” time.

A Stage-Based Approach to Therapy in Parkinson’s Disease

A practical, stage-based guide to pharmacological management of both motor and non-motor symptoms of PD is provided, to help the physician in yielding the best therapeutic strategies for each symptom and condition in patients with PD.

Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients

Geriatric patients with Parkinson’s disease experience a specific profile of comorbidities and an international register concerning issues of safer drug application and monitoring could help to implement a better treatment.

Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease

  • J. Finberg
  • Biology, Medicine
    Journal of Neural Transmission
  • 2018
The scientific background to the localization and function of the enzymes, the physiological changes resulting from their inhibition, and the basic and clinical pharmacology of the various inhibitors and their role in treatment of Parkinson’s disease are described.

Opicapone Protects Against Hyperhomocysteinemia-Induced Increase in Blood-Brain Barrier Permeability.

Results show that Opicapone protects against HHcy-induced BBB permeability by reducing the expression and gelatinase activity of MMPs, and increasing the expression of claudin-2.

Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms.

The main published treatment guidelines were reviewed based on the recommendations of group from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology, adapting the best evidence to the Brazilian reality.



Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

In the management of the motor complications seen in Parkinson's disease, tolcapone and entacapone can be used to reduce off time, reduce levodopa dose, and modestly improve motor impairment and disability.

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial

Treatment with a 50-mg once-daily dose of opicapone was associated with a significant reduction in mean daily off-time in levodopa-treated patients with PD and motor fluctuations, and this effect is maintained for at least 1 year.

New treatments for levodopa‐induced motor complications

Randomized controlled trials conducted in patients suffering from already established complications showed that new levodopa (l‐dopa) formulations such as intrajejunal l‐dop–carbidopa infusion and bilayered extended‐release l‐Dopa–car bidopa (IPX066) can improve motor fluctuations.

Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations

Tolcapone was effective at prolonging the clinical benefit oflevodopa and reducing total levodopa requirements in PD patients with motor fluctuations, and was well tolerated.

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations

Long-term entacapone treatment effectively prolonged the beneficial response to levodopa in parkinsonian patients with the wearing-off phenomenon, and improvement occurred irrespective of the reduction of thelevodopa dose.

Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment

Tolcapone appears to be beneficial in the treatment of patients with parkinsonism who have not yet developed motor fluctuations, and these improvements were maintained up to the 12-month assessment.

Disease‐modifying strategies for Parkinson's disease

  • L. KaliaS. KaliaA. Lang
  • Biology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 2015
Clinical trials of disease‐modifying therapies for PD that were published since 2013 as well as clinical trials currently in progress are summarized.